(Q53151022)

English

Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.

scientific article published on 24 June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

restless legs syndrome

1 reference

based on heuristic

inferred from title

5

object named as

Birgit Högl

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

Luigi Ferini Strambi

4

object named as

Luigi Ferini-Strambi

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

6

object named as

Werner Poewe

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

Claudia Trenkwalder

2

object named as

Claudia Trenkwalder

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

Wolfgang H. Oertel

1

object named as

Wolfgang Oertel

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

Karin Stiasny-Kolster

7

object named as

Karin Stiasny-Kolster

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

author name string

Heike Beneš

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

Andreas Fichtner

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

Erwin Schollmayer

9

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

Ralf Kohnen

10

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

Diego García-Borreguero

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

SP710 study group

12

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

publication date

24 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

10

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

710-720

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Restless legs syndrome prevalence and impact: REST general population study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Restless legs syndrome: pathophysiology, clinical presentation and management

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of pramipexole in restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dopaminergic augmentation of restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970127-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(11)70127-2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21705273

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53151022&oldid=1796401916"